Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.